Stop Addiction Stigma
- Conditions
- Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
- Interventions
- Behavioral: AssessmentOther: Educational ActivityOther: Training
- Registration Number
- NCT06582030
- Brief Summary
This clinical trial evaluates the impact of a Stop Addiction Stigma (SAS) training workshop with a short description of the conditions related to addiction (vignettes) on stigmatizing attitudes toward individuals with substance abuse disorders. Reviews have shown that patients with substance abuse disorders have experienced negative attitudes from their health care providers. Negative attitudes may lead to less involvement from the provider and the patient and may lead to less effective care. Using case vignettes with a SAS workshop may be an effective method to help people learn about addiction, reduce the stigma toward addiction and improve the quality of health care.
- Detailed Description
PRIMARY OBJECTIVE:
I. To describe the impact of SAS training on participants' responses to people with a substance impairment.
SECONDARY OBJECTIVES:
I. To evaluate the feasibility of stigma training workshops on stigmatizing attitudes health care personnel.
II. To explore the maintainability of responses over time. III. To explore relationships between language and stigmatizing attitudes.
OUTLINE: Participants are randomized to 1 of 6 group case vignettes.
GROUP A (CHRONICALLY RELAPSING BRAIN DISEASE): Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study.
GROUP B (BRAIN DISEASE): Participants view the brain disease vignette and attend a SAS workshop on study.
GROUP C (DISEASE): Participants view the disease vignette and attend a SAS workshop on study.
GROUP D (ILLNESS): Participants view the illness vignette and attend a SAS workshop on study.
GROUP E (DISORDER): Participants view the disorder vignette and attend a SAS workshop on study.
GROUP F (PROBLEM): Participants view the problem vignette and attend a SAS workshop on study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 93
- Employee of Ohio State University Wexner Medical Center (OSUWMC)
- Age ≥ 18 years
- Participants must be able to read and comprehend survey items
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group D (illness vignette, SAS) Educational Activity Participants view the illness vignette and attend a SAS workshop on study. Group D (illness vignette, SAS) Training Participants view the illness vignette and attend a SAS workshop on study. Group B (brain disease vignette, SAS) Educational Activity Participants view the brain disease vignette and attend a SAS workshop on study. Group B (brain disease vignette, SAS) Training Participants view the brain disease vignette and attend a SAS workshop on study. Group E (disorder vignette, SAS) Training Participants view the disorder vignette and attend a SAS workshop on study. Group F (problem vignette, SAS) Educational Activity Participants view the problem vignette and attend a SAS workshop on study. Group F (problem vignette, SAS) Training Participants view the problem vignette and attend a SAS workshop on study. Group C (disease vignette, SAS) Assessment Participants view the disease vignette and attend a SAS workshop on study. Group C (disease vignette, SAS) Educational Activity Participants view the disease vignette and attend a SAS workshop on study. Group F (problem vignette, SAS) Assessment Participants view the problem vignette and attend a SAS workshop on study. Group C (disease vignette, SAS) Training Participants view the disease vignette and attend a SAS workshop on study. Group D (illness vignette, SAS) Assessment Participants view the illness vignette and attend a SAS workshop on study. Group B (brain disease vignette, SAS) Assessment Participants view the brain disease vignette and attend a SAS workshop on study. Group A (chronically relapsing brain disease vignette, SAS) Assessment Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study. Group A (chronically relapsing brain disease vignette, SAS) Educational Activity Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study. Group E (disorder vignette, SAS) Assessment Participants view the disorder vignette and attend a SAS workshop on study. Group E (disorder vignette, SAS) Educational Activity Participants view the disorder vignette and attend a SAS workshop on study.
- Primary Outcome Measures
Name Time Method Stigmatizing attitudes Before, immediately after and 8 weeks after the session Stigmatizing attitudes will be measured with the Stigma and Attribution Assessment. The assessment score will be compared both between and within participants for each case vignette. Results will be reported with descriptive statistics, including means and standard deviations or medians and first-third quartiles for continuous variables, and frequencies and percentages for discrete variables.The linear mixed effect model will be used to study the repeated stigma and attribution measures over time (pre-workshop, immediately post-workshop, and 8 weeks post-workshop) within 6 vignettes as well as the effects between the vignettes, while controlling for the potential confounding factors (e.g., sex).
- Secondary Outcome Measures
Name Time Method Attendance rate At 90 minute session. The proportion of participants attending the workshop will be summarized with 95% confidence interval.
Response to post-workshop evaluations Before, immediately following and 8 weeks after the session. The proportion of participants who respond to the post-workshop evaluations will be summarized with 95% confidence interval.
Trial Locations
- Locations (1)
Ohio State University Comprehensive Cancer Center
🇺🇸Columbus, Ohio, United States